Democratic Republic of Congo News

Kinshasa—The Democratic Republic of the Congo has declared the end of its latest Ebola outbreak, thanks in part to the trusted infrastructure and expertise of the national polio eradication programme. 

Antimicrobial resistance (AMR) is one of the most pressing health challenges of our time. It threatens the effectiveness of treatments, increases healthcare costs, and endangers millions of lives.

We spoke with Dr Aurélie Mambu Nsimba, pharmacist and Head of the Regulatory Quality Assurance Office at the Congolese Pharmaceutical Regulatory Authority, to understand the issues and solutions.

Bulape, Democratic Republic of the Congo –Twenty-five-year-old Héritier Bope Mpona recalls with sadness the impact of Ebola on his life. He lost his daughter, wife and mother to the disease which affected his community of Bulape in the Democratic Republic of the Congo’s Kasai Province. “I came out alive, but I came out alone,” he says.

The outbreak was declared over on 1 December 2025, around three months after it was confirmed. Intense efforts to control and end the outbreak helped save lives, including Mpona’s.

Bulape — Ebola virus disease is a serious illness. When detected late, it claims many lives, even with recent advances in vaccines and therapeutics. Although the disease has become more manageable with improved care and as response capacities, it still takes a heavy toll on families and communities.

Bulape ‒ Fifty-four-year-old Jacob Mukaba, who lost his wife recently to Ebola, is observing a 40-day mourning period during which he must not leave his home. This practice among the Kete community in Bulape, a locality in the Democratic Republic of the Congo’s Kasai Province and the epicentre of the ongoing Ebola outbreak—is working to the advantage of disease surveillance teams.